CN Patent

CN116583303A — 雷公藤甲素缀合物和其用途

Assigned to Ruiyang Shanghai New Drug Development Co ltd · Expires 2023-08-11 · 3y expired

What this patent protects

本公开提供了雷公藤甲素缀合物、制备此类化合物的方法、包括此类化合物的药物组合物和药物以及使用此类化合物治疗病状/疾病，如与癌症、免疫调节和/或炎症相关的那些病状/疾病的方法。

USPTO Abstract

本公开提供了雷公藤甲素缀合物、制备此类化合物的方法、包括此类化合物的药物组合物和药物以及使用此类化合物治疗病状/疾病，如与癌症、免疫调节和/或炎症相关的那些病状/疾病的方法。

Drugs covered by this patent

Patent Metadata

Patent number
CN116583303A
Jurisdiction
CN
Classification
—
Expires
2023-08-11
Drug substance claim
No
Drug product claim
No
Assignee
Ruiyang Shanghai New Drug Development Co ltd
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.